Palma Rocchi

Dr. Palma Rocchi

Inserm
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Molecular Cell
Verified
Journal Article
Closed access
FRFran Robson
Fran Robson
KKKhadija Shahed Khan
Khadija Shahed Khan
TLThi Khanh Le
Thi Khanh Le
CPClément Paris
Clément Paris
SDSinem Demirbag
Sinem Demirbag
BNBilly Wai-Lung Ng
Billy Wai-Lung Ng

19 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TLThi Khanh LE
Thi Khanh LE
QDQuang Hieu DUONG
Quang Hieu DUONG
VBVirginie Baylot
Virginie Baylot
CFChristelle FARGETTE
Christelle FARGETTE
Michael BaboudjianMichael Baboudjian
Michael Baboudjian
Palma RocchiPalma Rocchi
Palma Rocchi
Prostate cancer (PC) is the second most common cancer in men worldwide. Despite recent advances in diagnosis and treatment, castration-resistant prostate cancer (CRPC) remains a significant medical challenge. Prostate cancer cells can develop mechanisms to resist androgen deprivation therapy, such as AR overexpression, AR mutations, alterations in AR coregulators, increased steroidogenic signaling pathways, outlaw pathways, and bypass pathways. Various treatment options for CRPC exist, including androgen deprivation therapy, chemotherapy, immunotherapy, localized or systemic therapeutic radiation, and PARP inhibitors. However, more research is needed to combat CRPC effectively. Further investigation into the underlying mechanisms of the disease and the development of new therapeutic strategies will be crucial in improving patient outcomes. The present work summarizes the current knowledge regarding the underlying mechanisms that promote CRPC, including both AR-dependent and independent pathways. Additionally, we provide an overview of the currently approved therapeutic options for CRPC, with special emphasis on chemotherapy, radiation therapy, immunotherapy, PARP inhibitors, and potential combination strategies.

18 January 2010 in Oncogene
Verified
Journal Article
Closed access
PDF file
CAC Andrieu
C Andrieu
DTD Taieb
D Taieb
VBV Baylot
V Baylot
SES Ettinger
S Ettinger
PSPhilippe Soubeyran
Philippe Soubeyran
Palma RocchiPalma Rocchi
Palma Rocchi

6 October 2014 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
MKMaria Katsogiannou
Maria Katsogiannou
CAClaudia Andrieu
Claudia Andrieu
Palma RocchiPalma Rocchi
Palma Rocchi
Understanding the mechanisms that control stress-induced survival is critical to explain how tumors frequently resist to treatment and to improve current anti-cancer therapies. Cancer cells are able to cope with stress and escape drug toxicity by regulating heat shock proteins (Hsps) expression and function. Hsp27 (HSPB1), a member of the small Hsp family, represents one of the key players of many signaling pathways contributing to tumorigenicity, treatment resistance, and apoptosis inhibition. Hsp27 is overexpressed in many types of cancer and its functions are regulated by post-translational modifications, such as phosphorylation. Protein phosphorylation is the most widespread signaling mechanism in eukaryotic cells, and it is involved in all fundamental cellular processes. Aberrant phosphorylation of Hsp27 has been associated with cancer but the molecular mechanisms by which it is implicated in cancer development and progression remain undefined. This mini-review focuses on the role of phosphorylation in Hsp27 functions in cancer cells and its potential usefulness as therapeutic target in cancer.

1 July 2014 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
JAJulie Acunzo
Julie Acunzo
VBVirginie Baylot
Virginie Baylot
ASAlan So
Alan So
Palma RocchiPalma Rocchi
Palma Rocchi

1 July 2015 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
MKMaria Katsogiannou
Maria Katsogiannou
HZHajer Ziouziou
Hajer Ziouziou
SKSara Karaki
Sara Karaki
CAClaudia Andrieu
Claudia Andrieu
MVMarie Henry de Villeneuve
Marie Henry de Villeneuve
Palma RocchiPalma Rocchi
Palma Rocchi